Ophthalmology
Sight Sciences touts eye pressure reduction with glaucoma OMNI device
US-based Sight Sciences has published the two-year post-surgical outcomes of its minimally invasive glaucoma surgery device, the OMNI surgical system.…
Ocugen to initiate Phase III trial of gene therapy for retinitis pigmentosa
Ocugen will soon be initiating a Phase III trial of its gene therapy candidate OCU400 for retinitis pigmentosa (RP). The…
LENZ reports positive results from presbyopia treatment trial
LENZ Therapeutics has reported positive topline data from the Phase III CLARITY study of two investigational formulations of aceclidine, LNZ100…
Pipeline Moves: Progression prospects for stuttering candidate increase after trial completion
This week on Pipeline Moves, we kick off by looking at a Phase II trial of Noema Pharma’s NOE-105 in…
Aurion doses first subject in Phase I/II corneal oedema trial in Canada
Aurion Biotech has dosed the first Canadian subject in the Phase I/II ABA-1, CLARA clinical trial of AURN001, a new…
Belite Bio seeks Japanese approval for Stargardt disease therapy trial
Belite Bio has submitted an application to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to begin a clinical trial…
Minocycline for dry AMD treatment shows no benefit in NIH trial
The US National Institutes of Health unit National Eye Institute (NEI) has reported that a Phase II clinical trial of…
Innovent’s macular degeneration drug trial meets primary endpoint
Chinese biotechnology company Innovent Biologics has reported that the Phase II clinical trial of efdamrofusp alfa high-dose (IBI302) in Chinese…
OcuTerra’s Phase II diabetic retinopathy trial misses endpoints
OcuTerra Therapeutics has reported that its Phase II DR:EAM clinical trial of selective RGD integrin inhibitor nesvategrast (OTT166) eye drops…
Ocugen completes first cohort dosing in geographic atrophy trial
Ocugen has announced the completion of subject dosing in the first cohort of its Phase I/II ArMaDa clinical trial of…
